Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H25NO3.ClH |
Molecular Weight | 315.836 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C
InChI
InChIKey=IPWGSXZCDPTDEH-UHFFFAOYSA-N
InChI=1S/C16H25NO3.ClH/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6;/h9-11H,7-8H2,1-6H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H25NO3 |
Molecular Weight | 279.3746 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/9711459Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of thymoxamine and pilocarpine on the depth of the anterior chamber. | 1980 Oct |
|
Effects of thymoxamine and its metabolites on clonidine-induced hypotension and bradycardia in rats. | 1982 Jul |
|
[Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients]. | 2001 Feb |
|
The esterase-like activity of serum albumin may be due to cholinesterase contamination. | 2001 Oct |
|
Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. | 2001 Oct |
|
Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence. | 2002 |
|
Alpha(1L)-, but not alpha(1H)-, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo. | 2002 Sep 27 |
|
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats. | 2006 Jan 30 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2522580
Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:01 GMT 2023
by
admin
on
Fri Dec 15 15:09:01 GMT 2023
|
Record UNII |
WK2KZM9V6X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
19887
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m7648
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
964-52-3
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
13758
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
SUB03343MIG
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
C87585
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
DTXSID9046946
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
170448
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL159226
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
WK2KZM9V6X
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
213-519-4
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
235778
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000088303
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |